Total non-dilutive funding of up to USD 159 million upon completion of predefined milestones, including near-term committed funding of USD 6 million Allschwil, Switzerland, September 25, 2025 Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial and fungal infections,…
Read More
Basilea announces in-licensing of a novel clinical phase 3-ready oral antibiotic Allschwil, Switzerland, August 14, 2025 Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial and fungal infections, announced today that it has entered into an exclusive license agreement…
Read More
Venatorx Pharmaceuticals Announces Changes to Executive Leadership See more here
Read More
Venatorx Pharmaceuticals Expands Senior Leadership Team Key Hires in CMC/Technical Operations, Business Development, and Finance See more here
Read More
Venatorx and Melinta Provide Update on Status of U.S. New Drug Application for Cefepime-Taniborbactam No Clinical Safety or Efficacy Issues Identified No Requirement for Further Clinical Data or Trials See more here
Read More
New England Journal of Medicine Publishes Positive Results of Cefepime-Taniborbactam from Phase 3 CERTAIN-1 Study of Patients with Complicated Urinary Tract Infection Cefepime-Taniborbactam Superior to Meropenem for the Composite Efficacy Endpoint Composite Efficacy Sustained at Late Follow-up Visit Safety Profile Consistent with Meropenem See more here
Read More
Venatorx Pharmaceuticals and Menarini Group Enter Commercial Agreement for Cefepime-Taniborbactam in 96 Countries See more here
Read More
Melinta Therapeutics and Venatorx Pharmaceuticals Announce Licensing Agreement to Commercialize Cefepime-Taniborbactam in the U.S. See more here
Read More
Venatorx Pharmaceuticals Awarded a Third Antibiotic BARDA Contract Total award of up to $167 million for development of novel oral antibiotic ceftibuten-ledaborbactam etzadroxil for treatment of complicated urinary tract infection (cUTI), including pyelonephritis See more here
Read More
Venatorx Pharmaceuticals to Present at IDWeek 2023 - New data to be presented from Phase 3 CERTAIN-1 study with Cefepime-Taniborbactam - MD Anderson Cancer Center analysis of Cefepime-Taniborbactam in vitro activity against clinically significant gram-negative bacteria isolated from patients with cancer See more here
Read More